





APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/389,545	09/03/1999	COLIN R. DUNSTAN	A-605	5554
21069 7	590 07/01/2002		ı	
AMGEN INCORPORATED MAIL STOP 27-4-A ONE AMGEN CENTER DRIVE			EXAMINER	
			HELMS, LARRY RONALD	
THOUSAND	OAKS, CA 91320-1799		ART UNIT PAPER NUMBER	
			1642	10
			DATE MAILED: 07/01/2002	طا

Please find below and/or attached an Office communication concerning this application or proceeding.

*** A	Application N .	Applicant(s)			
Advisory Action	09/389,545	DUNSTAN, COLIN F	₹.		
i i i i i i i i i i i i i i i i i i i	Examiner	Art Unit			
•	Larry R. Helms	1642			
The MAILING DATE of this communicati n appears on the cover sheet with the correspondence address					
THE REPLY FILED 06 May 2002 FAILS TO PLACE THIS Therefore, further action by the applicant is required to average final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applicated at the control of the control o	ation. A proper reply n places the applica	y to a tion in		
PERIOD FOR REPLY [check either a) or b)]					
a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire land ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the context	divisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THE date on which the petition under 37 CFI f extension and the corresponding amothe shortened statutory period for reply the later than three months after the mail	g date of the final rejection IE FINAL REJECTION. R 1.136(a) and the apprount of the fee. The appropriationally set in the final	on. See MPEP  ppriate extension opriate extension Office action; or		
1. A Notice of Appeal was filed on <u>06 May 2002</u> . Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.					
2. The proposed amendment(s) will not be entered be					
(a) ⊠ they raise new issues that would require furthe	·	see NOTE below);			
(b) ☐ they raise the issue of new matter (see Note below);					
(c) they are not deemed to place the application ir issues for appeal; and/or		-			
(d) they present additional claims without canceling	ng a corresponding number of fi	nally rejected claims	S.		
NOTE: <u>See Continuation Sheet</u> .					
3. Applicant's reply has overcome the following rejection	on(s): <u>IF IF IF entered the 112 sec</u>	ond rejection.			
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed	amendment		
5. ☑ The a) ☐ affidavit, b) ☐ exhibit, or c) ☑ request for application in condition for allowance because: see		dered but does NO	Γ place the		
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY to	o issues which were	enewly		
7. For purposes of Appeal, the proposed amendments explanation of how the new or amended claims we			ind an		
The status of the claim(s) is (or will be) as follows:	•				
Claim(s) allowed: none.					
Claim(s) objected to: none.					
Claim(s) rejected: <u>23-40</u> .					
Claim(s) withdrawn from consideration:					
8. The proposed drawing correction filed on is a	a)∏ approved or b)∏ disappi	roved by the Examir	ner.		
9. $\square$ Note the attached Information Disclosure Statemen	it(s)( PTO-1449) Paper No(s)	·			
10. Other:		PRIMARY EXAMINE	full		
Petrot and Tradewall Office					

Continuation of 2. NOTE: previous claims 25-40 have been cancelled and new claims 41-58 encompas a method of preventing or treating loss of bone mass resulting from lytic bone disease associated with cancer. The newly added claims would require a new search because the claims now require the lytic bone disease to be cancer associated..